Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

(Pedi-EVOLVE Trial)

This trial explores whether a combination of oral estrogen and progestin, specifically Norethindrone Acetate-Ethinyl Estradiol, can stimulate the release of oxytocin, a hormone linked to bonding and stress relief, in individuals with certain hormone deficiencies. It includes two groups: those with hypopituitary disease, which affects hormone production, and those with a specific hormone deficiency called AVP-D. Participants will take a single dose of the medication, and researchers will check their hormone levels. This trial suits individuals diagnosed with AVP-D or hypopituitary disease who have stable hormone replacement therapy. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking medical discoveries.

If you are currently taking estrogen/progestin, you will need to stop for at least 6 weeks before the main study visits. For other medications, there should be no changes within 2 weeks of enrollment or within 5 half-lives of the medication.

Research has shown that norethindrone acetate and ethinyl estradiol are generally safe for people. These ingredients, commonly found in birth control pills, have been used safely for many years. Other studies have indicated that a single dose of these hormones does not cause significant side effects, and participants did not report major health problems after using them.

Most treatments for oxytocin deficiency focus on directly supplementing oxytocin levels or using oxytocin analogs. However, Norethindrone Acetate-Ethinyl Estradiol offers a fresh approach. Researchers are excited because this combination could potentially regulate hormonal imbalances differently, possibly impacting oxytocin levels in a new way. By targeting the hormonal axis, this treatment might provide benefits beyond just replacing oxytocin, addressing the root causes of deficiency more holistically. This could lead to more comprehensive symptom relief for patients with hypopituitary disease.

Research has shown that a combination of two hormones, norethindrone acetate and ethinyl estradiol, might help increase oxytocin levels. Oxytocin plays a crucial role in social connections and emotional regulation. Early findings suggest that this hormone combination could boost oxytocin in individuals with a condition affecting hormone balance. In this trial, participants with hypopituitary disease, both with and without arginine-vasopressin deficiency (AVP-D), will receive norethindrone acetate-ethinyl estradiol to evaluate its effects on oxytocin levels. Previous studies have demonstrated that even a single dose can alter oxytocin levels. However, further research is needed to understand its effectiveness in treating low oxytocin levels.¹²³⁶⁷